Amsbio offers a comprehensive range of pre-made lentiviral particles for delivering target genes into most types of dividing and non-dividing mammalian cells in vitro and in vivo.

Lentiviral particles provide long-term, stable expression of genes, making them ideal for stable cell line engineering, CRISPR applications, and therapeutic gene transfer.

Key advantages of Amsbio lentiviral particles include their ease of use, high titer, purity, and safety features. These pre-made lentiviral particles come ready-to-use, eliminating the need for transfection reagents and saving up to 4 weeks of work. The high-titer formulation of these particles (>1x10⁷ IFU / mL) ensures high transduction efficiency for both adherent and suspension cells. Using proprietary third-generation, self-inactivating (SIN) vectors, Amsbio lentiviral particles are safe to use requiring only BSL-2 containment.

These advantages make Amsbio a strong choice for applications in gene knockdown/overexpression, CAR-T cell manufacturing, and in vivo studies. Drawing upon decades of experience and expertise – Amsbio can offer top quality pre-made lentiviral particles ranging from research-grade to GMP-grade for clinical applications.

In a new published study – US researchers describe using lentivirus supplied by Amsbio to help investigate the impact of the RNA binding protein (HuR) on CC-chemokine ligand 2 (CCL2) expression. This pioneering study identifies the molecular mechanism behind why certain individuals produce more CCL2, a protein linked to chronic inflammatory diseases like HIV-associated neurocognitive disorder and atherosclerosis. To read the study in full please visit https://elifesciences.org/articles/93108.

For further information on pre-made lentiviral particles please visit https://www.amsbio.com/products/cells-cell-culture/viral-delivery/lentiviral-particles or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.